IKT Inhibikase Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1750149 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-45.1%
TTM EPS YoY-185.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-52.9%
ROA-49.2%
ROIC (approx.)-68.9%
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio15.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | $0 | $0 | — | $0 | $0 | $0 | $0 |
| R&D expense | $15.00M | $13.39M | $10.84M | $6.36M | $7.65M | $5.27M | $10.51M | $7.19M |
| SG&A expense | $7.23M | $7.66M | $7.38M | $6.77M | $5.61M | $5.92M | $5.25M | $5.74M |
| Operating income | -$22.23M | -$21.05M | -$17.84M | -$13.78M | -$12.77M | -$10.83M | -$14.60M | -$12.93M |
| Income tax | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$20.47M | -$19.59M | -$16.38M | -$12.73M | -$11.93M | -$9.92M | -$13.68M | -$12.13M |
| EBITDA | -$22.23M | -$21.05M | -$17.84M | -$13.78M | -$12.74M | -$10.81M | -$14.59M | -$12.92M |
| EPS (basic) | -0.10 | -0.11 | -0.10 | — | -0.13 | -0.11 | -0.15 | — |
| EPS (diluted) | -0.10 | -0.11 | -0.10 | — | -0.13 | -0.11 | -0.15 | — |
| Weighted avg. shares (diluted) | 196.94M | 174.57M | 172.31M | — | 90.05M | 90.01M | 89.54M | — |
| Banking | ||||||||
| Net interest income | $1.76M | $1.46M | $1.46M | $1.04M | $838,093 | $916,755 | $919,271 | $796,123 |
| Balance sheet | ||||||||
| Cash & equivalents | $51.70M | $31.21M | $49.57M | $139.22M | $38.27M | $77.74M | $73.44M | $56.49M |
| Short-term investments | $141.62M | $127.81M | $120.80M | $39.54M | $39.05M | $9.92M | $19.74M | $41.05M |
| Current assets | $198.73M | $162.34M | $172.18M | $180.11M | $78.54M | $88.79M | $94.16M | $98.45M |
| PP&E, net | — | — | — | $0 | $0 | $23,687 | $47,845 | $47,100 |
| Total assets | $201.75M | $163.59M | $173.33M | $181.20M | $79.59M | $88.85M | $94.28M | $98.60M |
| Current liabilities | $12.96M | $10.26M | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M |
| Short-term debt | — | — | — | $0 | $0 | $37,944 | $74,772 | $110,517 |
| Total liabilities | $12.96M | $10.26M | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M |
| Shareholders' equity | $188.80M | $153.33M | $167.62M | $172.90M | $72.90M | $80.05M | $85.73M | $94.87M |
| Shares outstanding | 140.27M | 132.03M | 132.03M | 131.69M | 74.81M | 74.52M | 74.34M | 69.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.35M | -$12.44M | -$12.06M | -$7.52M | -$10.59M | -$5.57M | -$4.10M | -$5.35M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $13,399 | $0 |
| Free cash flow | -$17.35M | -$12.44M | -$12.06M | -$7.52M | -$10.59M | -$5.57M | -$4.12M | -$5.35M |
| Investing cash flow | -$12.61M | -$5.91M | -$80.48M | -$98,847 | -$28.75M | $9.84M | $21.05M | -$38.76M |
| Financing cash flow | $50.46M | -$14,489 | $2.90M | $108.57M | -$134,130 | $31,771 | $0 | $99.68M |
| Depreciation & amortization | $0 | $0 | $0 | $0 | $23,688 | $24,157 | $12,654 | $6,567 |
| Stock-based compensation | $5.53M | $5.35M | $5.56M | $4.53M | $4.53M | $4.21M | $2.04M | $7.91M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.